Michael Phelan and Jonathan Petty | Virginia Trial Attorneys

Xarelto: a blood thinner that can cause fatal bleeding

For decades, the tried-and-true blood thinner Warfarin (Coumadin) helped men and women prevent blood clots, lower the risk of stroke, treat deep vein thrombosis and pulmonary embolism, and treat other blood and heart related issues.

A newer class of blood thinners, including Xarelto (rivaroxaban), have been marketed as lifestyle drugs – easier to take than Warfarin. The problems with these new drugs, particularly Xarelto, include that they are less effective and less safe than Warfarin. In some cases, it is critical that your blood be able to clot (for example, if you are severely wounded or experience internal bleeding). Warfarin has an easy to administer anecdote, which, in an emergency, allows physicians to reverse its blood thinning properties. Unlike warfarin, there is no known antidote to Xarelto’s anti-clotting mechanism. The dangers posed by this phenomenon should be obvious: a patient can bleed to death. If you are taking Xarelto, talk to your doctor about its dangers immediately. And if you or a loved one was hospitalized for a bleeding event within a few days of taking Xarelto, call us today.

UPDATE: The start of the Xarelto bellwether trials is set to begin later this month (March 2017). While the outcomes of bellwether trials are not binding on other cases, the bellwether trials are designed to help attorneys for both sides, insurers, litigants and judges determine case values and facilitate future settlements of Xarelto cases. The first case is scheduled to begin on March 13 in the Eastern District of Louisiana. The second trial is set to begin on April 24.

If you or a loved one has been injured by Xarelto, call the Virginia Xarelto lawyers at Phelan Petty, PLC at 804-980-7100 or toll free at 866-249-3164 for a free consultation. You may also request a free consultation by clicking on our Contact Form, which will be reviewed by one of our Virginia Xarelto attorneys.

Related blogs: